Radiopharma biotech Aktis sees Big Pharma backers return for $175M series B

Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that saw the U.S. Big Pharma rejoin a range of big-name investors in the radiopharma biotech.